

Hans Mg Princen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10914545/publications.pdf>

Version: 2024-02-01

33
papers

2,688
citations

257450

24
h-index

414414

32
g-index

33
all docs

33
docs citations

33
times ranked

3655
citing authors

#	ARTICLE	IF	CITATIONS
1	No effects of PCSK9-inhibitor treatment on spatial learning, locomotor activity, and novel object recognition in mice. <i>Behavioural Brain Research</i> , 2021, 396, 112875.	2.2	3
2	Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. <i>Journal of Lipid Research</i> , 2020, 61, 365-375.	4.2	48
3	The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. <i>European Heart Journal</i> , 2017, 38, 2499-2507.	2.2	176
4	Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 211-221.	27.0	633
5	Comment on "Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice" by Rebholz S.L. et al. <i>Toxicol. Rep.</i> 2016 (3) 46-54. <i>Toxicology Reports</i> , 2016, 3, 306-309.	3.3	11
6	Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes. <i>British Journal of Pharmacology</i> , 2015, 172, 5293-5305.	5.4	29
7	Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising A systematic review and meta-analysis of relevant preclinical studies and clinical trials. <i>European Journal of Pharmacology</i> , 2015, 763, 48-63.	3.5	44
8	Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. <i>Journal of Lipid Research</i> , 2015, 56, 2085-2093.	4.2	27
9	PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. <i>Journal of Lipid Research</i> , 2014, 55, 2370-2379.	4.2	59
10	Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. <i>Journal of Lipid Research</i> , 2014, 55, 2103-2112.	4.2	165
11	Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice. <i>Journal of Nutritional Biochemistry</i> , 2013, 24, 1423-1430.	4.2	49
12	Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. <i>Journal of Hypertension</i> , 2012, 30, 107-116.	0.5	27
13	Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice. <i>Biochemical Pharmacology</i> , 2012, 84, 821-829.	4.4	21
14	Perfluoroalkyl Sulfonates Cause Alkyl Chain Length-Dependent Hepatic Steatosis and Hypolipidemia Mainly by Impairing Lipoprotein Production in APOE*3-Leiden CETP Mice. <i>Toxicological Sciences</i> , 2011, 123, 290-303.	3.1	118
15	Fenofibrate Increases Very Low Density Lipoprotein Triglyceride Production Despite Reducing Plasma Triglyceride Levels in APOE*3-Leiden.CETP Mice. <i>Journal of Biological Chemistry</i> , 2010, 285, 25168-25175.	3.4	28
16	Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 2016-2022.	2.4	161
17	Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. <i>Atherosclerosis</i> , 2008, 197, 57-63.	0.8	76
18	Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin. <i>Circulation</i> , 2008, 117, 2515-2522.	1.6	89

#	ARTICLE	IF	CITATIONS
19	Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. <i>Journal of Lipid Research</i> , 2007, 48, 1763-1771.	4.2	86
20	Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. <i>Journal of Hypertension</i> , 2007, 25, 2454-2462.	0.5	27
21	Modification of Low-Density Lipoprotein by Methylglyoxal Alters its Physico-Chemical and Biological Properties. , 2005, , 285-290.		1
22	Absence of an atheroprotective effect of the garlic powder printanor in APOE*3-Leiden transgenic mice. <i>Atherosclerosis</i> , 2004, 177, 291-297.	0.8	13
23	Increased Fecal Bile Acid Excretion in Transgenic Mice With Elevated Expression of Human Phospholipid Transfer Protein. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 892-897.	2.4	56
24	Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterolâ€“Lowering Effect in APOE*3-Leiden Transgenic Mice. <i>Circulation</i> , 2003, 108, 1368-1374.	1.6	157
25	Fibrates Suppress Fibrinogen Gene Expression in Rodents Via Activation of the Peroxisome Proliferator-Activated Receptor-ïœ€. <i>Blood</i> , 1999, 93, 2991-2998.	1.4	127
26	Plasma coenzyme Q10concentrations are not decreased in male patients with coronary atherosclerosis. <i>Free Radical Research</i> , 1999, 30, 165-172.	3.3	6
27	Oxidation of LDL and extent of peripheral atherosclerosis. <i>Free Radical Research</i> , 1999, 31, 129-139.	3.3	10
28	Fibrates Suppress Fibrinogen Gene Expression in Rodents Via Activation of the Peroxisome Proliferator-Activated Receptor-ïœ€. <i>Blood</i> , 1999, 93, 2991-2998.	1.4	39
29	Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?. <i>Atherosclerosis</i> , 1998, 140, 15-24.	0.8	67
30	Effect of methylglyoxal on the physico-chemical and biological properties of low-density lipoprotein. <i>Lipids and Lipid Metabolism</i> , 1998, 1394, 187-198.	2.6	23
31	Seasonal Variation in Low Density Lipoprotein Oxidation and Antioxidant Status. <i>Free Radical Research</i> , 1997, 27, 89-96.	3.3	11
32	Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. <i>Atherosclerosis</i> , 1996, 122, 245-253.	0.8	104
33	Supplementation With Low Doses of Vitamin E Protects LDL From Lipid Peroxidation in Men and Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 325-333.	2.4	197